ArticleDiagnostics (Basel, Switzerland)2020
Biochemical Markers of Saliva in Lung Cancer: Diagnostic and Prognostic Perspectives.
Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Extraoral Detection of Biomarkers and Pathogens in Saliva: Comprehensive, Panoramic Review.Biosensors · 2026Review
- Salivary genetic biomarkers of lung cancer: a systematic review and meta-analysis of the diagnostic accuracy.Cancer cell international · 2025Review
- BreathERJ open research · 2025Article
- Identification of Salivary Biomarkers in Colorectal Cancer by Integrating Olink Proteomics and Metabolomics.Journal of proteome research · 2025Article
- Computational and experimental microfluidics: Total analysis system for mixing, sorting, and concentrating particles and cells.APL bioengineering · 2024Article
- Salivary metabolomic biomarkers for non-invasive lung cancer detection.Cancer science · 2024Article
- Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics.Genes & diseases · 2023Review
- «Salivaomics» of Different Molecular Biological Subtypes of Breast Cancer.Current issues in molecular biology · 2022Article
- Prognostic Value of Salivary Biochemical Indicators in Primary Resectable Breast Cancer.Metabolites · 2022Article
- MALDI-TOF/MS Analysis of Non-Invasive Human Urine and Saliva Samples for the Identification of New Cancer Biomarkers.Molecules (Basel, Switzerland) · 2022Review
- Metabolic Features of Saliva in Breast Cancer Patients.Metabolites · 2022Article
- Differential diagnosis of lung cancer and benign lung lesion using salivary metabolites: A preliminary study.Thoracic cancer · 2022Article
- Application of Non-Blood-Derived Fluid Biopsy in Monitoring Minimal Residual Diseases of Lung Cancer.Frontiers in surgery · 2022Review
- Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva.Diagnostics (Basel, Switzerland) · 2021Article
- Features of the Metabolic Profile of Saliva in Lung Cancer and COPD: The Effect of Smoking Status.Metabolites · 2021Article
- Molecular biomarkers in early stage lung cancer.Translational lung cancer research · 2021Review
- Salivary Biomarkers in Lung Cancer.Mediators of inflammation · 2021Review
- Salivary Metabolic Profile of Patients with Lung Cancer, Chronic Obstructive Pulmonary Disease of Varying Severity and Their Comorbidity: A Preliminary Study.Diagnostics (Basel, Switzerland) · 2020Article
- Diagnostic and Prognostic Value of Salivary Biochemical Markers in Oral Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the work is to study the metabolic characteristics of saliva in lung cancer for use in early diagnosis and determining the prognosis of the disease. The patient group included 425 lung cancer patients, 168 patients with non-cancerous lung diseases, and 550 healthy volunteers. Saliva samples were collected from all participants in the experiment before treatment and 34 biochemical saliva parameters were determined. Participants were monitored for six years to assess survival rates. The statistical analysis was performed by means of Statistica 10.0 (StatSoft) program and R package (version 3.2.3). To construct the classifier, the Random Forest method was used; the classification quality was assessed using the cross-validation method. Prognostic factors were analyzed by multivariate analysis using Cox's proportional hazard model in a backward step-wise fashion to adjust for potential confounding factors. A complex of metabolic changes occurring in saliva in lung cancer is described. Seven biochemical parameters were identified (catalase, triene conjugates, Schiff bases, pH, sialic acids, alkaline phosphatase, chlorides), which were used to construct the classifier. The sensitivity and specificity of the method were 69.5% and 87.5%, which is practically not inferior to the diagnostic characteristics of markers routinely used in the diagnosis of lung cancer. Significant independent factors in the poor prognosis of lung cancer are imidazole compounds (ICs) above 0.478 mmol/L and salivary lactate dehydrogenase activity below 545 U/L. Saliva has been shown to have great potential for the development of diagnostic and prognostic tests for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.